

**January 27, 2026**

1. Listing Department  
National Stock Exchange of India Limited  
Plot No. C/1, 'G' Block, Exchange Plaza, Scrip: NECLIFE  
Bandra Kurla Complex, Bandra (East), Mumbai- 400 051.

2. Corporate Communications Department  
BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street, Scrip Code: 532649  
Mumbai- 400 001.

3. Board of Directors  
Nureca Limited ("Company")  
Andheri West B-205, Bldg -42, B wing, Dhanashree heights,  
Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053.

**Sub: Disclosure under Regulation 10(6) of the Securities and Exchange Board of India ("SEBI") (Substantial Acquisition of Shares and Takeovers) Regulations, 2011("Takeover Regulations")**

Dear Sir/Madam,

In reference to cited subject, please find attached herewith report under Regulation 10(6) of the Takeover Regulations in the prescribed format pursuant to exemption provided under Regulation 10(4)(c) of the Takeover Regulations.

This is for your kind information and record please.

Thanking you,

For and on behalf of  
**Acquirers being members of Promoter and Promoter Group**

**Saurabh Goyal      Aryan Goyal      Payal Goyal      Smita Goyal**

**Saurabh Goyal**  
**(On behalf of Nectar Biopharma Private Limited)**  
**Director**  
**DIN: 00136037**

**Place: Chandigarh**

**Joint Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“Takeover Regulations”)**

1.	Name of the Target Company (TC)	Nureca Limited (“TC” or “Company”)	
2.	Name of the acquirer(s)	Promoter and Promoter Group 1. Saurabh Goyal 2. Aryan Goyal 3. Payal Goyal 4. Smita Goyal 5. Nectar Biopharma Private Limited	
3.	Name of the stock exchange where shares of the TC are listed	1. BSE Limited 2. National Stock Exchange of India Limited	
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares	This change is consequent to the buyback of equity shares of the Company, which opened on December 18, 2025 and closed on December 24, 2025, and the subsequent extinguishment of shares on January 07, 2026. Thereby %age in equity share capital and Voting Rights in the Company have been increased, though there have no change in the number of shares held.	
5.	Relevant regulation under which the acquirer is exempted from making open offer	Regulation 10 (4) (c) of Takeover Regulations.	
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	No prior intimation was required to be submitted under Regulation 10(5) of the Takeover Regulations, as the said transaction falls under exemption provided under Regulation 10(4)(c).	
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made
	a.	Name of the transferor / seller	Not Applicable( “NA”) NA
	b.	Date of acquisition	NA NA
	c.	Number of shares/ voting rights in respect of the acquisitions from each	NA NA

		person mentioned in 7(a) above				
	d.	Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	NA		NA	
	e.	Price at which shares are proposed to be acquired / actually acquired	NA		NA	
8.	Shareholding details		Pre-Transaction		Post-Transaction	
			No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a	Each Acquirer / Transferee(*)				
	i)	Saurabh Goyal	32,17,214	32.17	32,17,214	33.72
	ii)	Aryan Goyal	11,59,185	11.59	11,59,185	12.15
	iii)	Payal Goyal	20,59,928	20.60	20,59,928	21.59
	iv)	Smita Goyal	7	0.00	7	0.00
	v)	Nectar Biopharma Private Limited	60,842	0.61	60,842	0.64
		<b>Total</b>	64,97,176	64.97	64,97,176	68.09
	b	Each Seller / Transferor	NA	NA	NA	NA

**Note:**

(\*) Shareholding of each entity shall be shown separately and then collectively in a group. The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

The individual equity shareholding details of promoter and promoters' group in the Company before and after buyback is attached herewith as Annexure 1.

For and on behalf of

**Acquirers being members of Promoter and Promoter Group**

**Saurabh Goyal**

**Aryan Goyal**

**Payal Goyal**

**Smita Goyal**

**Saurabh Goyal**

**(On behalf of Nectar Biopharma Private Limited)**

**Director**

**DIN: 00136037**

**Place: Chandigarh**

## Annexure 1

## Shareholding details of promoter and promoters' group of Nureca Limited

Name of Acquirer	Before the Buyback		Buy Back		After the Buyback		Difference
	No. of shares /voting rights	% w.r.t total share capital of TC	No. of shares / voting rights	% w.r.t total share capital of TC	No. of shares /voting rights	% w.r.t total share capital of TC	
Saurabh Goyal	32,17,214	32.17	0	-	32,17,214	33.72	1.55
Aryan Goyal	11,59,185	11.59	0	-	11,59,185	12.15	0.56
Payal Goyal	20,59,928	20.60	0	-	20,59,928	21.59	0.99
Smita Goyal	7	0.00	0	-	7	0.00	0.00
Nectar Biopharma Private Limited	60,842	0.61	0	-	60,842	0.64	0.03
<b>Promoters Total</b>	<b>64,97,176</b>	<b>64.97</b>	<b>0</b>	<b>-</b>	<b>64,97,176</b>	<b>68.09</b>	<b>3.12</b>
Public	35,02,999	35.03	-4,58,255	(04.58)	30,44,744	31.91	-3.12
<b>Total</b>	<b>1,00,00,175</b>	<b>100.00</b>	<b>-4,58,255</b>	<b>(04.58)</b>	<b>95,41,920</b>	<b>100.00</b>	<b>-</b>